In 2013 phase 2a, a randomized, double-blind, placebo-controlled, dose-ranging study evaluated the efficacy and safety of the anti-IL-17 in patients with inadequately controlled moderate to severe asthma, not statistically significant in clinical efficacy on ACQ were observed, neither in lung function nor asthma symptoms [120]. The gene discussed is IL17A; the disease is asthma.